Quick Answer
Immunome Inc. reported Operating Income of -$224.11 million for fiscal year 2025.
Immunome Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$224.11M | +26.7% |
| 2024 | -$305.80M | -179.2% |
| 2023 | -$109.53M | -196.8% |
| 2022 | -$36.90M | -46.4% |
| 2021 | -$25.20M | -105.6% |
| 2020 | -$12.26M | -18.5% |
| 2019 | -$10.35M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$60.14M | -19.0% | -29.4% |
| June 30, 2025 | -$46.48M | -16.2% | -4.1% |
| March 31, 2025 | -$44.64M | +66.3% | +11.7% |
| September 30, 2024 | -$50.52M | -990.5% | -26.3% |
| June 30, 2024 | -$40.01M | -593.0% | +69.8% |
| March 31, 2024 | -$132.30M | -2859.0% | -2755.6% |
| September 30, 2023 | -$4.63M | +45.7% | +19.7% |
| June 30, 2023 | -$5.77M | +35.3% | -29.1% |
- Immunome Inc. showed an increase of +26.7% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Immunome Inc.’s operating income has declined by 2065.8% (from -$10.35 million to -$224.11 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: